Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 08, 2023

SELL
$33.58 - $41.2 $272,199 - $333,967
-8,106 Reduced 30.5%
18,473 $660,000
Q4 2022

Feb 13, 2023

BUY
$37.12 - $46.52 $16,778 - $21,027
452 Added 1.73%
26,579 $1 Million
Q3 2022

Nov 14, 2022

SELL
$36.54 - $48.66 $40,559 - $54,012
-1,110 Reduced 4.08%
26,127 $1.16 Million
Q2 2022

Aug 15, 2022

BUY
$31.71 - $43.0 $281,426 - $381,625
8,875 Added 48.33%
27,237 $1.01 Million
Q1 2022

May 13, 2022

BUY
$29.88 - $37.04 $421,576 - $522,597
14,109 Added 331.74%
18,362 $680,000
Q3 2021

Nov 15, 2021

BUY
$33.54 - $40.55 $5,467 - $6,609
163 Added 3.99%
4,253 $143,000
Q2 2021

Aug 16, 2021

BUY
$34.54 - $47.25 $141,268 - $193,252
4,090 New
4,090 $163,000
Q1 2021

May 13, 2021

SELL
$42.51 - $63.78 $324,011 - $486,131
-7,622 Closed
0 $0
Q4 2020

Feb 12, 2021

BUY
$45.3 - $60.27 $815 - $1,084
18 Added 0.24%
7,622 $431,000
Q3 2020

Nov 12, 2020

SELL
$47.45 - $62.95 $11,957 - $15,863
-252 Reduced 3.21%
7,604 $361,000
Q2 2020

Aug 13, 2020

SELL
$46.85 - $61.05 $2.36 Million - $3.08 Million
-50,379 Reduced 86.51%
7,856 $463,000
Q1 2020

May 13, 2020

BUY
$41.6 - $63.4 $2.05 Million - $3.12 Million
49,217 Added 545.76%
58,235 $2.75 Million
Q4 2019

Feb 14, 2020

BUY
$53.85 - $65.27 $393,051 - $476,405
7,299 Added 424.61%
9,018 $545,000
Q3 2019

Nov 14, 2019

SELL
$59.06 - $72.15 $7.62 Million - $9.31 Million
-129,104 Reduced 98.69%
1,719 $103,000
Q2 2019

Aug 14, 2019

SELL
$62.09 - $86.14 $8.51 Million - $11.8 Million
-137,055 Reduced 51.16%
130,823 $8.41 Million
Q1 2019

May 10, 2019

BUY
$52.92 - $81.17 $7.05 Million - $10.8 Million
133,178 Added 98.87%
267,878 $21.7 Million
Q4 2018

Feb 13, 2019

BUY
$43.37 - $59.54 $5.84 Million - $8.02 Million
134,700 New
134,700 $7.28 Million

Others Institutions Holding IONS

About IONIS PHARMACEUTICALS INC


  • Ticker IONS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 141,940,992
  • Market Cap $5.64B
  • Description
  • Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...
More about IONS
Track This Portfolio

Track Federated Hermes, Inc. Portfolio

Follow Federated Hermes, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Federated Hermes, Inc. with notifications on news.